Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0151-9638(05)79518-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic efficacy of against phenylhydrazine-induced hemolytic anemia in rats.
J Tradit Complement Med
January 2025
School of Chemical & Biotechnology, SASTRA Deemed University, Thanjavur, India.
Background & Aim: Hemolytic anemia is a blood disorder whose incidence is increasing in the world in recent years especially after the pandemic. Conventional treatments include use of steroids and immunosuppresants that are accompanied by numerous adverse effects. With growing interest in using complex multi-component formulations for multi-targeted therapy, the present study aims to investigate the therapeutic efficacy of a traditional herbomineral preparation, , which has been traditionally used as a supplement in iron-deficiency anemia, against phenylhydrazine-induced hemolytic anemia in rodent models.
View Article and Find Full Text PDFINTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
J Prev Alzheimers Dis
January 2025
CenExel iResearch, Atlanta, GA, USA.
Background: Soluble species of multimeric amyloid-beta including globular amyloid-beta oligomers (AβOs) and linear amyloid-beta protofibrils are toxic to neurons. Sabirnetug (ACU193) is a humanized monoclonal antibody, raised against globular species of soluble AβO, that has over 650-fold greater binding affinity for AβOs over monomers and appears to have relatively little binding to amyloid plaque.
Objectives: To assess safety, pharmacokinetics, and exploratory measures including target engagement, biomarker effects, and clinical efficacy of sabirnetug in participants with early symptomatic Alzheimer's disease (AD; defined as mild cognitive impairment and mild dementia due to AD).
Purpose: Radioiodine-131 (RAI or iodine-131) is one of the most frequently used radionuclides for diagnosis and therapy of thyroid diseases (90% of all therapies in nuclear medicine). In order to optimize the patient protection, it is important to evaluate the long-term biological effects of RAI therapy on non-target organs.
Materials And Methods: An experimental animal model has been adopted, it consists on miming RAI therapy.
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.
Innov Pharm
March 2024
OhioHealth Riverside Methodist Hospital, Columbus, OH.
Article Synopsis
- - The FDA has approved lecanemab as a treatment for Alzheimer's disease, targeting Aβ protofibrils and showing promise in slowing disease progression in mild cases.
- - In clinical trials, lecanemab demonstrated a modest improvement in clinical decline and a reduction of amyloid proteins, although the significance of this impact is still debated.
- - While lecanemab offers benefits, it comes with serious risks like brain swelling and microhemorrhages, and it is quite expensive at $26,500 per year, raising questions about access to treatment.
Validation for the function of protein C in mouse models.
PeerJ
April 2024
Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Guangdong Medical University, Zhanjiang, Guangdong, China.
Article Synopsis
- The study focused on Protein C (PC), an important anticoagulant, and discovered a specific mutation in the PROC gene associated with autosomal recessive PC deficiency (PCD) using CRISPR/Cas9 gene editing in mice.
- The results showed that while heterozygous mice had no severe bleeding or thrombosis, they did experience some health issues, including blindness and liver and kidney abnormalities, alongside significant reductions in PC activity compared to wild-type mice.
- Ultimately, this research successfully validated the functional role of PC in mice and highlighted various health impacts linked to the specific genetic mutation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!